Literature DB >> 22109693

Quality of life following DBS in the caudal zona incerta in patients with essential tremor.

Ulrika Sandvik1, Gun-Marie Hariz, Patric Blomstedt.   

Abstract

BACKGROUND: Essential tremor (ET) is the most common movement disorder and often affects the quality of life. There are only a few studies evaluating the quality of life after deep brain stimulation (DBS).
FINDINGS: This is a prospective study of 16 patients undergoing deep brain stimulation in the caudal Zona incerta (cZi). The quality of life was assessed with Quality of Life in Essential Tremor Questionnaire (QUEST) and SF-36 scores, and the tremor was evaluated using the essential tremor rating scale (ETRS).
RESULTS: In the tremor rating, hand tremor on the treated side improved by 95%, hand function by 78% and activities of daily living by 71%. The QUEST score showed statistically significant improvements in the psychosocial and activities of daily living subscores. The SF-36 score did not show any significant improvement.
CONCLUSIONS: Although very good tremor reduction was achieved, the improvement in the quality of life scores was more modest. This could partly be explained by the quality of life being affected by other factors than the tremor itself.

Entities:  

Mesh:

Year:  2011        PMID: 22109693     DOI: 10.1007/s00701-011-1230-z

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  10 in total

1.  Imaging for deep brain stimulation: The zona incerta at 7 Tesla.

Authors:  Hans U Kerl; Lars Gerigk; Marc A Brockmann; Sonia Huck; Mansour Al-Zghloul; Christoph Groden; Thomas Hauser; Armin M Nagel; Ingo S Nölte
Journal:  World J Radiol       Date:  2013-01-28

2.  Visualisation of the zona incerta for deep brain stimulation at 3.0 Tesla.

Authors:  H U Kerl; L Gerigk; S Huck; M Al-Zghloul; C Groden; I S Nölte
Journal:  Clin Neuroradiol       Date:  2012-02-17       Impact factor: 3.649

3.  Tremor-related quality of life: A comparison of essential tremor vs. Parkinson's disease patients.

Authors:  Elan D Louis; Duarte G Machado
Journal:  Parkinsonism Relat Disord       Date:  2015-04-24       Impact factor: 4.891

4.  Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study.

Authors:  Anthony Langone; Steven M Steinberg; Roberto Gedaly; Laurence K Chan; Tariq Shah; Kapil D Sethi; Vincenza Nigro; John C Morgan
Journal:  Clin Transplant       Date:  2015-08-06       Impact factor: 2.863

5.  Ventral Intermediate Nucleus Versus Zona Incerta Region Deep Brain Stimulation in Essential Tremor.

Authors:  Robert S Eisinger; Joshua Wong; Leonardo Almeida; Adolfo Ramirez-Zamora; Jackson N Cagle; Juan C Giugni; Bilal Ahmed; Alberto R Bona; Erin Monari; Aparna Wagle Shukla; Christopher W Hess; Justin D Hilliard; Kelly D Foote; Aysegul Gunduz; Michael S Okun; Daniel Martinez-Ramirez
Journal:  Mov Disord Clin Pract       Date:  2017-11-27

6.  A Pilot Double-Blind Randomized Trial of Perampanel for Essential Tremor.

Authors:  Adrian Handforth; Winona Tse; Rodger J Elble
Journal:  Mov Disord Clin Pract       Date:  2020-03-31

Review 7.  Current clinical application of deep-brain stimulation for essential tremor.

Authors:  Amit Chopra; Bryan T Klassen; Matt Stead
Journal:  Neuropsychiatr Dis Treat       Date:  2013-12-02       Impact factor: 2.570

8.  [The use of neuromodulation for the treatment of tremor].

Authors:  Damián Bendersky; Pablo Ajler; Claudio Yampolsky
Journal:  Surg Neurol Int       Date:  2014-08-04

Review 9.  Outcomes from stereotactic surgery for essential tremor.

Authors:  Robert Francis Dallapiazza; Darrin J Lee; Philippe De Vloo; Anton Fomenko; Clement Hamani; Mojgan Hodaie; Suneil K Kalia; Alfonso Fasano; Andres M Lozano
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-10-18       Impact factor: 10.154

Review 10.  Managing Essential Tremor.

Authors:  Franziska Hopfner; Günther Deuschl
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 6.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.